Newsfiscal.ai
Chardan Initiates Tvardi Therapeutics at Buy With $8 Price Target
· Published
Article summary
Chardan Capital has initiated coverage on Tvardi Therapeutics, assigning the company a 'Buy' rating and a price target of $8.00.
An excerpt from the original article.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…